Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEVAC RVF is a veterinary vaccine developed by Middle East for Vaccines (MEVAC) for the active immunization of ruminants, including cattle, sheep, and goats, against Rift Valley Fever (RVF). RVF is a significant viral zoonotic disease caused by the Rift Valley fever virus (RVFV), which is transmitted by mosquitoes and can lead to severe clinical disease, high mortality in young animals, and widespread 'abortion storms' in livestock. The vaccine is formulated as an inactivated viral suspension, typically adjuvanted with aluminum hydroxide to enhance the immune response. By using an inactivated platform, MEVAC RVF provides a safe alternative to live-attenuated vaccines, eliminating the risk of viral reversion or accidental transmission to humans while effectively stimulating protective humoral and cellular immunity in the target species.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MEVAC RVF.